“…Despite the fact that many of investigational and approved medicinal agents are 1,3,5‐triazine derivatives, there are little published reports on stability of those agents, particularly in the solid state 3–8. Moreover, there are no reports in the pharmaceutical literature regarding degradation profile of any pyrazolo‐[1,5‐a]‐1,3,5‐triazine derivatives.…”